Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
GSK Beats Q1 Earnings & Sales Estimates, Ups 2024 Guidance
12:11pm, Wednesday, 01'st May 2024
GSK's revenues benefit from strong growth across the Specialty Medicines and Vaccines segments. The company raises guidance for earnings and sales for the full year.
GSK (GSK) Q1 Earnings and Revenues Surpass Estimates
08:05am, Wednesday, 01'st May 2024
GSK (GSK) came out with quarterly earnings of $1.09 per share, beating the Zacks Consensus Estimate of $0.94 per share. This compares to earnings of $0.90 per share a year ago.
GSK beginning to alleviate long-held concerns, say analysts
04:31am, Wednesday, 01'st May 2024
GSK PLC (LSE:GSK, NYSE:GSK) is approaching 18-month highs after the pharma group's boss Emma Walmsley raised the full-year outlook on the back of strong first-quarter results, with analysts saying pe
GSK Q1 beats consensus and FY numbers upgraded after vaccines boost
03:12am, Wednesday, 01'st May 2024
GSK PLC (LSE:GSK, NYSE:GSK) has confirmed what recent prescription data hinted at: Its vaccines business is firing on all cylinders. Bumper sales of jabs for shingles and the cold-like condition RSV w
GSK raises full-year profit forecast
02:08am, Wednesday, 01'st May 2024
GSK raised its full-year profit forecast on Wednesday, betting on strong demand for its common respiratory virus and shingles vaccines.
FTC Warns ‘Junk Patents' Could Make Drugs Like Ozempic Pricier—Here's How
01:56pm, Tuesday, 30'th Apr 2024
The Federal Trade Commission is challenging hundreds of alleged “junk” patent listings filed by several pharmaceutical companies, which regulators claim could increase prices for medications like
FTC challenges ‘bogus' patents on Ozempic, other drugs that ‘block competition'
01:30pm, Tuesday, 30'th Apr 2024
WASHINGTON — Federal regulators are challenging patents on 20 brand-name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting in
Forget the Fed. These 3 Stocks Will Soar No Matter What
06:19am, Monday, 29'th Apr 2024
Few experts expect the U.S. Federal Reserve to raise interest rates this year. And Fed Chairman Jerome Powell still has not ruled out the possibility of the central bank cutting rates in 2024.
Why the Market Dipped But GSK (GSK) Gained Today
07:21pm, Thursday, 25'th Apr 2024
In the most recent trading session, GSK (GSK) closed at $40.91, indicating a +0.12% shift from the previous trading day.
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
09:40am, Thursday, 25'th Apr 2024
GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-1
GSK (GSK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:08am, Wednesday, 24'th Apr 2024
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GSK Gears Up for Q1 Earnings: Here's What to Expect
02:21pm, Tuesday, 23'rd Apr 2024
We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.
Why the Market Dipped But GSK (GSK) Gained Today
07:20pm, Friday, 19'th Apr 2024
In the latest trading session, GSK (GSK) closed at $39.75, marking a +1.22% move from the previous day.
Why GSK (GSK) is a Top Value Stock for the Long-Term
10:46am, Wednesday, 17'th Apr 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GSK Announces FDA Acceptance of New Meningococcal Jab BLA
09:16am, Wednesday, 17'th Apr 2024
The approval of GSK's 5-in-1 meningococcal ABCWY vaccine candidate, MenABCWY, could provide the broadest meningococcal serogroup coverage and lead to simplified immunization.
